This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluate the Efficacy and Safety of N02RS1 in Patient With Acute Bronchitis

This study has been completed.
Information provided by (Responsible Party):
PharmaKing Identifier:
First received: December 8, 2015
Last updated: March 29, 2016
Last verified: March 2016
A multi center, randomized, double-blind, placebo-controlled, parallel, phase 2b clinical trial to evaluate the efficacy and safety of N02RS1 in patients with acute bronchitis

Condition Intervention Phase
Acute Bronchitis Drug: N02RS1 1200mg Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi Center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of N02RS1 in Patients With Acute Bronchitis

Resource links provided by NLM:

Further study details as provided by PharmaKing:

Primary Outcome Measures:
  • BSS(Bronchitis Severity Score) score variation compared to baseline after 7 days [ Time Frame: Visit 1(-3days, screening), 2(0day, randomization), 3(3days), 4(8days) ]

Enrollment: 108
Study Start Date: December 2015
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: N02RS1 1200mg
Combination of Broussonetia spp and Lonicera spp
Drug: N02RS1 1200mg
1200mg/day, Three times a day orally, 2 tablets once, 7 days
Placebo Comparator: Placebo
sugar pill
Drug: Placebo
1200mg/day, Three times a day orally, 2 tablets once, 7 days

Detailed Description:
Suitable subjects randomized to the experimental or control group. The subjects eat IP during 7days. Visit 3(3 days) evaluate BSS through phone call and visit 4(8 days) evaluate efficacy and safety.

Ages Eligible for Study:   19 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients over 19, under 75 of age
  • Patients acute bronchitis, sputum symptoms, BSS over 7 points.
  • Patients acute bronchitis within 7days.
  • Non-pregnant, patients who agree to contraception.
  • Patients who can write diary and available to communicate.
  • Patients voluntarily agreed

Exclusion Criteria:

  • Patients with hypersensitivity to the drug.
  • Patients who have gotten systemic steroid treatment within 4 weeks.
  • Patients who have gotten treatment of antibiotics, bronchodilators, painkiller and secretagog within 7 days.
  • Patients who have gotten treatment of mucus solvents or antitussives within 3 days.
  • Patients who serious respiratory infections requiring antibiotic treatment, allergic bronchial asthma, bronchiectasis and chronic obstructive pulmonary disease.
  • Patients heart disease, severe kidney, liver disease.
  • The bleeding tendency or immunosuppressed patients.
  • Patients with clinically significant abnormal values.
  • Pregnant women or nursing mothers.
  • Patients alcoholics or drug abuse.
  • Patients taking other clinical trail's medicines within 30 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: PharmaKing Identifier: NCT02637310     History of Changes
Other Study ID Numbers: PMK-N02RS1_Phase 2B
Study First Received: December 8, 2015
Last Updated: March 29, 2016

Additional relevant MeSH terms:
Acute Disease
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Disease Attributes
Pathologic Processes processed this record on August 18, 2017